The abstract is read at the publisher; the summary is JClub's.
IGF/IGFBP axis alterations are linked to cancer-associated sarcopenia, with insulin-like growth factor binding protein 1 and insulin-like growth factor binding protein 2 suggested as endocrine mediators.
- Why it matters: Cancer-associated muscle wasting drives treatment toxicity and mortality, but the endocrine links between tumor signals, liver changes, and impaired muscle repair remain unclear.
- What they did: Mechanistic work reviewed how the IGF/IGFBP axis connects tumor-derived cues, hepatic reprogramming, and defective muscle regeneration, and how aging may shift this axis and reduce anabolic/regenerative capacity.
- The result: The IGF/IGFBP axis is identified as a promising source of biomarkers and potential therapeutic targets for cancer-associated muscle wasting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.